{"id":"NCT03261999","sponsor":"Foresee Pharmaceuticals Co., Ltd.","briefTitle":"Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer","officialTitle":"An Open-Label, Single-Arm Study of The Efficacy, Safety, and Pharmacokinetic Behavior of Leuprolide Mesylate Injectable Suspension (LMIS 25 mg) in Subjects With Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-26","primaryCompletion":"2018-11-19","completion":"2019-02-01","firstPosted":"2017-08-25","resultsPosted":"2020-05-04","lastUpdate":"2020-05-04"},"enrollment":144,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostatic Neoplasms"],"interventions":[{"type":"DRUG","name":"Leuprolide Mesylate","otherNames":[]}],"arms":[{"label":"Leuprolide Mesylate 25mg","type":"EXPERIMENTAL"}],"summary":"The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with prostate cancer, when administered as two injections twelve weeks apart.","primaryOutcome":{"measure":"Efficacy of Leuprolide Mesylate (LMIS 25mg)","timeFrame":"168 days","effectByArm":[{"arm":"Leuprolide Mesylate 25mg","deltaMin":97.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":21,"countries":["United States","Czechia","Lithuania","Slovakia","South Korea"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":144},"commonTop":["hot flush","Hypertension","weight increased","Injection site haemorrhage"]}}